Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma

Tania Jain, Craig S. Sauter, Gunjan L. Shah, Molly A. Maloy, Jason Chan, Michael Scordo, Scott T. Avecilla, Yakup Batlevi, Parastoo B. Dahi, Connie W. Batlevi, M. Lia Palomba, Sergio A. Giralt, Miguel Angel Perales

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)2540-2544
Number of pages5
JournalLeukemia
Volume33
Issue number10
DOIs
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Jain, T., Sauter, C. S., Shah, G. L., Maloy, M. A., Chan, J., Scordo, M., Avecilla, S. T., Batlevi, Y., Dahi, P. B., Batlevi, C. W., Lia Palomba, M., Giralt, S. A., & Perales, M. A. (2019). Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. Leukemia, 33(10), 2540-2544. https://doi.org/10.1038/s41375-019-0476-y